Complete Guide to Oxfendazole Population Pharmacokinetics
Overview
Oxfendazole Population is a Benzimidazole Anthelminthic used in the Infectious Disease therapeutic area. It is indicated for Onchocerciasis (river blindness). Interactive population PK simulator for oxfendazole tablet formulation. Drug-metabolite model with first-pass metabolism and dose-limited bioavailability for onchocerciasis dose optimization.
Mechanism of Action
Oxfendazole Population exerts its pharmacological effect by targeting Onchocerca volvulus (adult worms). As a Benzimidazole Anthelminthic, it modulates this target to achieve therapeutic efficacy in Onchocerciasis (river blindness). Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Population PK (1-CMT drug-metabolite, first-pass) models for Oxfendazole Population:
| Parameter | Value |
|---|---|
| doses | 100mg single, 400mg single, 400mg QD x 5 days |
| method | NONMEM FOCE-I |
| drug name | Oxfendazole |
| Ka | 0.695 1/h |
| V F | 67.2 L |
| f M | 0.5 - |
| CL F | 3.54 L/h |
| f FP | 0.0549 - |
| V FEN F | 3370 L |
| V SO2 F | 206 L |
| CL FEN F | 94.4 L/h |
| CL SO2 F | 15.8 L/h |
| reference weight | 70 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Oxfendazole Population is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Infectious Disease therapeutic area, for the treatment of Onchocerciasis (river blindness), understanding the pharmacokinetics of Oxfendazole Population is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Oxfendazole Population pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Oxfendazole Population PK Simulator
Explore Oxfendazole Population pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Oxfendazole Population?
The elimination half-life of Oxfendazole Population depends on patient-specific factors. Use our interactive Oxfendazole Population PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Oxfendazole Population administered?
Oxfendazole Population is administered via the Oral route. It is indicated for Onchocerciasis (river blindness). As a Benzimidazole Anthelminthic, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Oxfendazole Population?
Key pharmacokinetic parameters for Oxfendazole Population include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Oxfendazole Population dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Oxfendazole Population PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.